Troyen Brennan - 21 Feb 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Chief Medical Officer
Signature
/s/ Troyen Brennan
Issuer symbol
CVS
Transactions as of
21 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 15:22:11 UTC
Previous filing
04 Feb 2022
Next filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Award $0 +171,944 +122% $0.000000 312,815 21 Feb 2022 Direct F1
holding CVS Common Stock (restricted) 4,805 21 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 53,772 21 Feb 2022 Common Stock 53,772 $104.82 Direct F2
holding CVS Stock Option 75,134 21 Feb 2022 Common Stock 75,134 $78.05 Direct F3
holding CVS Stock Option 21,894 21 Feb 2022 Common Stock 21,894 $62.21 Direct F4
holding CVS Stock Option 80,803 21 Feb 2022 Common Stock 80,803 $54.19 Direct F5
holding CVS Stock Option 84,478 21 Feb 2022 Common Stock 84,478 $58.34 Direct F6, F7
holding CVS Stock Option 99,344 21 Feb 2022 Common Stock 99,344 $74.30 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on June 5, 2019. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 21, 2022.
F2 Option became exercisable in four equal annual installments, commencing 4/1/2017.
F3 Option became exercisable in four equal annual installments, commencing 4/3/2018.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2019.
F5 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F6 The number of shares subject to the option were calculated using a 30-day average price.
F7 Options became exercisable in four equal annual installments, commencing 4/1/2021.
F8 Option becomes exercisable in four equal annual installments, commencing 4/1/2022.